Lopinavir/Ritonavir Accord (Lopinavir, Ritonavir)

Lopinavir targets the HIV‑1 protease enzyme, a key catalyst that cleaves viral polyprotein precursors into functional proteins required for new virus particles. By inhibiting this protease, lopinavir prevents the maturation of infectious virions, thereby reducing viral replication and allowing the immune system to recover.

The dosing regimen for Lopinavir/Ritonavir Accord is individualized by the prescribing clinician based on factors such as patient age, weight, treatment history, and co‑administered medications. Healthcare providers follow current clinical guidelines to determine the appropriate tablet strength and frequency for each patient.

Safety data for Lopinavir/Ritonavir during pregnancy and lactation are limited, and the product does not have a definitive pregnancy category. Clinicians must weigh potential benefits against unknown risks, and the decision to use the medication in pregnant or nursing individuals should be made on a case‑by‑case basis.

To request Lopinavir/Ritonavir Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Lopinavir/Ritonavir is a fixed‑dose combination that offers potent antiviral activity and a built‑in pharmacokinetic booster (ritonavir). Compared with other protease inhibitors such as darunavir, it may have a different side‑effect profile, particularly higher rates of lipid abnormalities, but provides a convenient single‑tablet regimen that simplifies dosing for many patients.

Lopinavir/Ritonavir Accord tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

The medication is taken orally as a tablet, usually with food to improve absorption and reduce gastrointestinal discomfort. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider, without crushing or splitting the tablet unless specifically instructed.

Serious adverse events include hepatotoxicity (liver enzyme elevations or hepatitis), pancreatitis, and severe allergic reactions such as rash, angioedema, or anaphylaxis. Patients should be monitored regularly for signs of liver dysfunction, abdominal pain, or hypersensitivity, and any concerning symptoms should prompt immediate medical evaluation.

Individuals with known hypersensitivity to lopinavir, ritonavir, or any excipients in the tablet should avoid the product. It is also contraindicated in patients with severe hepatic impairment or those taking medications that have a documented major interaction that cannot be managed, such as strong CYP3A4 inducers.